Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective.

Related Articles

Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective.

Vascul Pharmacol. 2017 Jan 07;:

Authors: Missiaen R, Rodriguez FM, Eelen G, Carmeliet P

Abstract
Current anti-angiogenic therapies in malignant and ocular diseases target growth factor signaling in order to attenuate excessive vascular growth. Although initial responses are promising, overall therapeutic success is limited due to insufficient efficiency, tumor refractoriness and resistance. Emerging evidence suggests that diverse growth factor signaling pathways in endothelial cells (ECs) converge onto cellular metabolism, creating an attractive target for novel alternative anti-angiogenic therapies. Recent studies show that ECs rely on glycolysis for ATP and biomass synthesis, necessary for proliferation and migration, key processes of angiogenesis. In addition, fatty acid β-oxidation (FAO) is essential for de novo nucleotide synthesis during EC proliferation. Initial proof-of-evidence has been given that administration of pharmacological inhibitors of those metabolic pathways can be used to inhibit pathological angiogenesis in vivo. Deciphering the role of other metabolic pathways and exploring the therapeutic potential of blocking these pathways await further investigation.

PMID: 28082117 [PubMed - as supplied by publisher]

http://ift.tt/2jPItwJ